Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,780 | 2,910 | 20:33 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.10. | Hansa Biopharma AB: Hansa Biopharma to Attend Truist Securities BioPharma Symposium | 165 | PR Newswire | LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York... ► Artikel lesen | |
18.10. | Telefonkonferenz zu Quartalszahlen: Hansa Biopharma meldet Rekordumsatz für IDEFIRIX im dritten Quartal 2024 | 2 | Investing.com Deutsch | ||
18.10. | Earnings call: Hansa Biopharma reports record IDEFIRIX sales in Q3 2024 | 2 | Investing.com | ||
17.10. | Hansa Biopharma Q3 GAAP EPS of -SEK 1.53, revenue of SEK78.4M | 1 | Seeking Alpha | ||
17.10. | Hansa Biopharma AB: Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results | 157 | PR Newswire | Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance
LUND, Sweden, Oct. 17, 2024 /PRNewswire/ -- Hansa Biopharma... ► Artikel lesen | |
07.10. | Hansa Biopharma AB: Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial | 182 | PR Newswire | LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from... ► Artikel lesen | |
03.10. | HANSA BIOPHARMA AB: Hansa Biopharma to host Q3 2024 interim results conference call | 9 | Cision News | ||
05.09. | Hansa Biopharma AB: Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference | 210 | PR Newswire | LUND, Sweden, Sept. 5, 2024 /PRNewswire/ -- Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial... ► Artikel lesen | |
23.08. | Hansa Biopharma AB: Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis | 800 | PR Newswire | LUND, Sweden, Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US... ► Artikel lesen | |
22.07. | Earnings call: Hansa Biopharma reports solid Q2 with growth in Idefirix sales | 3 | Investing.com | ||
18.07. | Hansa Biopharma Q2 GAAP EPS of -SEK3.30 | 1 | Seeking Alpha | ||
18.07. | Hansa Biopharma AB: Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update | 462 | PR Newswire | LUND, Sweden, July 18, 2024 /PRNewswire/ -- Hansa Biopharma today announced its first half and second quarter 2024 financial results and business update.
Søren Tulstrup, President and... ► Artikel lesen | |
03.07. | Hansa Biopharma AB: Hansa Biopharma to host Q2 2024 interim results conference call | 285 | PR Newswire | LUND, Sweden, July 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may... ► Artikel lesen | |
28.06. | Hansa Biopharma AB: Hansa Biopharma: increase in number of shares and votes | 696 | PR Newswire | LUND, Sweden, June 28, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa Biopharma" or the "Company") (NASDAQ: HNSA) (STOCKHOLM: HNSA) today announced that Hansa's registered share capital... ► Artikel lesen | |
27.06. | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | 1 | Cision News | ||
07.06. | HANSA BIOPHARMA AB: Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm | 5 | Cision News | ||
31.05. | Hansa Biopharma AB: Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial | 805 | PR Newswire | LUND, Sweden, May 31, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial... ► Artikel lesen | |
27.05. | Notice to Annual General Meeting in Hansa Biopharma AB (publ) | 4 | Cision News | ||
21.05. | Hansa Biopharma AB: Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting | 257 | PR Newswire | LUND, Sweden, May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant... ► Artikel lesen | |
03.05. | Hansa Biopharma AB: Hansa Biopharma: increase in number of shares and votes | 404 | PR Newswire | LUND, Sweden, May 3, 2024 /PRNewswire/ -- Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 104,50 | 0,00 % | Die Spannung steigt! Quartalszahlen von BioNTech und Evotec, Verdoppler bei BioNxt Solutions, Grenke und SMCI sind möglich | Die Berichtssaison ist gerade angelaufen und schon gibt es die ersten Gewinnwarnungen. Grenke warnt vor zunehmenden Rückstellungen, Super Micro Computer will gerne Zahlen einreichen, aber der Wirtschaftsprüfer... ► Artikel lesen | |
EVOTEC | 7,635 | -2,92 % | BASF, Commerzbank, Deutsche Telekom, Evotec, Linde, Volkswagen - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
CUREVAC | 2,612 | +0,23 % | CureVac holt Malkomes in den Vorstand | CureVac beruft Axel Sven Malkomes zum neuen CFO der Gesellschaft. "Die Ernennung gilt mit Wirkung zum 11. November 2024. Herr Malkomes bringt über drei Jahrzehnte Erfahrung in Unternehmensführung und... ► Artikel lesen | |
MODERNA | 43,815 | -5,91 % | Ihre wichtigsten Termine: Heute: Pinterest, Moderna, Airbnb, Daimler Truck& Delivery Hero legen Zahlen vor | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45... ► Artikel lesen | |
NOVAVAX | 8,319 | -2,05 % | Novavax, Inc.: Åsa Manelius Named Managing Director of Novavax AB Site | GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that Åsa Manelius... ► Artikel lesen | |
HEIDELBERG PHARMA | 2,410 | +0,42 % | Heidelberg Pharma Aktie: Große Schritte für kleines Risiko | Die Heidelberg Pharma AG verzeichnet weiterhin einen erfreulichen Aufwärtstrend an der Börse. Am 1. November 2024 stieg der Aktienkurs um 1,60% auf 2,545 EUR. Diese positive Entwicklung setzt sich auch... ► Artikel lesen | |
4SC | 5,420 | -3,21 % | 4SC: Bis in das erste Quartal 2026 hinein finanziert | 4SC hat Eckdaten für den Stichtag 30. September 2024 gemeldet. In den ersten neun Monaten habe es im Durchschnitt operativ einen Mittelabfluss von 0,6 Millionen Euro pro Monat gegeben. Dies liegt am... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 5,220 | +2,15 % | Inovio Pharmaceuticals Inc. Q2 Loss Decreases | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) revealed Loss for second quarter that decreased from the same period last yearThe company's bottom line totaled -$32.24 million, or -$1.19... ► Artikel lesen | |
INFLARX | 1,411 | -0,07 % | InflaRx Aktie: Starkes Vertrauen am Markt! | ||
SCORPIUS | 0,879 | +9,06 % | Scorpius Partners with Celltheon to Provide Cell Line Development Services | ||
TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
DYNAVAX | 12,430 | +11,78 % | Dynavax Technologies: Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates | HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth
Hepatitis B adult vaccine market expected to expand to a peak... ► Artikel lesen | |
BIOMARIN PHARMACEUTICAL | 61,90 | -0,10 % | Here's Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) | ||
IDEXX LABORATORIES | 404,50 | +0,87 % | IDEXX Laboratories' SWOT analysis: veterinary diagnostics leader faces market shifts | ||
VAXART | 0,669 | -0,52 % | Vaxart, Inc.: Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | - 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator... ► Artikel lesen |